Literature DB >> 23942738

[Surgery of inferior vena cava-associated urological tumor lesions].

M Weber1, F Meyer, U B Liehr, Z Halloul.   

Abstract

BACKGROUND: Tumor lesions of the inferior vena cava are extremely challenging with regard to adequate therapeutic management also in advanced malignant urological tumor lesions which can be caused by malignant adhesion, impression and tumor infiltration from the surrounding tissue. This can be the case with metastases from a seminoma or testicular carcinoma (differential diagnosis: primary vena cava leiomyosarcoma), tumor-associated growth into and within the inferior vena cava originating from renal cell carcinoma or carcinoma of the pararenal gland. The aim of this overview was to summarize current clinical and operative experiences in the treatment of inferior vena cava-associated urological tumor lesions, perioperative management, individual-specific and finding-adapted surgical technique and possible outcome, including prognostic considerations from clinical daily practice and representative data found in the literature. BASIC STATEMENTS: The primary aim of the surgical approach is to achieve R0 resection with reconstruction of the inferior vena cava lumen providing a reasonable risk-benefit ratio, which comprises i) complete resection and substitution of the inferior vena cava by a prosthesis along the previous extent of tumor growth, ii) partial resection of the vena cava wall with subsequent patch-plasty or tangential resection with primary suture or iii) removal of the vena cava thrombus after cavotomy. Particular attention should be paid to tumor thrombi reaching the right atrium which need to be extracted after sternotomy and atriotomy using an extracorporeal circulation (cardiac surgeon). For surgical planning, subdivision of the inferior vena cava into three segments, infracardiac, infrahepatic and infrarenal third, has been proven and tested.
CONCLUSIONS: The current development status and advances in surgical approaches as well as advances in medical technology allow the successful approach to such advanced stage urological tumor manifestations. A deciding factor is the abdominal and cardiovascular surgical expertise of each surgeon after formation of a team of surgical specialists (including urologists) and only then prognostic advantages can be achieved.

Entities:  

Mesh:

Year:  2013        PMID: 23942738     DOI: 10.1007/s00120-013-3202-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  36 in total

Review 1.  Update on surgical management of renal cell carcinoma with venous extension.

Authors:  Javier González
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

2.  Major vascular resection and prosthetic replacement for retroperitoneal tumors.

Authors:  Philipp Fueglistaler; Lorenz Gurke; Peter Stierli; Tamim Obeid; Christoph Koella; Daniel Oertli; Christoph Kettelhack
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

3.  Surgery for renal cell cancer extending into the inferior vena cava - evaluation of survival and perioperative complications using a standardized classification system.

Authors:  Stefan Zastrow; Steffen Leike; Sven Oehlschläger; Marc-Oliver Grimm; Manfred Wirth
Journal:  BJU Int       Date:  2011-06-28       Impact factor: 5.588

4.  Leiomyosarcoma of the inferior vena cava: experience in 22 cases.

Authors:  Edouard Kieffer; Mustapha Alaoui; Jean-Charles Piette; Patrice Cacoub; Laurent Chiche
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

5.  Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava.

Authors:  Marco Fiore; Chiara Colombo; Piermarco Locati; Mattia Berselli; Stefano Radaelli; Carlo Morosi; Paolo G Casali; Alessandro Gronchi
Journal:  Ann Surg Oncol       Date:  2011-07-27       Impact factor: 5.344

Review 6.  Imaging primary and secondary tumor thrombus of the inferior vena cava: multi-detector computed tomography and magnetic resonance imaging.

Authors:  Carlos Cuevas; Molly Raske; William H Bush; Thomas Takayama; Jeffrey H Maki; Orpheus Kolokythas; Emily Meshberg
Journal:  Curr Probl Diagn Radiol       Date:  2006 May-Jun

Review 7.  Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.

Authors:  Axel Bex; Eric Jonasch; Ziya Kirkali; Arnaud Mejean; Peter Mulders; Stephane Oudard; Jean-Jacques Patard; Thomas Powles; Hendrik van Poppel; Christopher G Wood
Journal:  Eur Urol       Date:  2010-08-27       Impact factor: 20.096

8.  Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

Authors:  Axel Bex; Astrid A M van der Veldt; Christian Blank; Alfons J M van den Eertwegh; Epie Boven; Simon Horenblas; John Haanen
Journal:  World J Urol       Date:  2009-01-15       Impact factor: 4.226

9.  Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.

Authors:  Bernd Wagner; Jean-Jacques Patard; Arnaud Méjean; Karim Bensalah; Grégory Verhoest; Richard Zigeuner; Vincenzo Ficarra; Jacques Tostain; Peter Mulders; Denis Chautard; Jean-Luc Descotes; Alexandre de la Taille; Laurent Salomon; Tommaso Prayer-Galetti; Luca Cindolo; Antoine Valéri; Nicolas Meyer; Didier Jacqmin; Hervé Lang
Journal:  Eur Urol       Date:  2008-08-05       Impact factor: 20.096

Review 10.  Surgery in metastatic testicular cancer.

Authors:  Peter Albers; Diethild Melchior; Stefan C Müller
Journal:  Eur Urol       Date:  2003-08       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.